Papel de la leflunomida en la Artritis Reumatoide

Revista Espanola de Reumatologia

Volumn 27, Issue 6, 2000, Pages 281-287

  Rodríguez De La Serna, Arturo ^a,b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 23644447764     PISSN: 03044815     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Egido J, Gómez Reino JJ, Herrero Beaumont G, Rodríguez de la Serna A. Manual de inflamación. Madrid: Medical & Marketing Communications, 1999.
2. Egasmone C, Lund B, Borg G, Pettersson H, Berg E, Brodin V et al. Patientes with rheumatoid arthritis benefit from early 2nd line therapy: 5 years follow-up of a prospective double blind placebo controlled study. J Rheumatol 1995; 22: 2208-13.
3. Markenson JA. Worldwide trends in the socioeconomic impact and long-term prognosis of rheumatoid arthritis. Sem Arthritis Rheum 1991; 21 (Supl 1): 4-12.
4. Pincus T, Callaham LF. Reassessment of twelve traditional paradigms concerning the diagnosis, prevalence, morbidity and mortality of rheumatoid arthritis. Scand J Rheumatol 1989; 79 (Supl): 67-95.
5. Rodríguez de la Serna A. Impacto socioeconómico de la artritis reumatoide. Rev Clin Esp 2000; 200. En prensa.
6. Popovic S, Bartlett R. Disease modifying activity of HWA 486 on the development of SLE in the MRL/lpr mouse. Agents Actions 1986; 19: 313-4.
7. Popovic S, Bartlett R. The use of the murine chronic graft-vs-host (CGVH) disease, a model for systemic lupus erythematosus (SLE) for drug discovery. Agents Actions 1987; 21: 284-6.
8. Gland T, Milecz K, Bartlett R. Immunomodulation of proteoglycan-induced progressive polyarthritis by leflunomide. Immunopharmacology 1991; 23: 105-16.
9. Stosic-Grujicic S, Dimitrijevic M, Bartlett R. A novel immunomodulating agent-leflunomide inhibits experimental autoimmune diabetes in mice. Transplant Proc 1996; 28: 3072-3.
10. Bartlett R, Schleyerbach R. Immunopharmacologic properties of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity.I. Disease modifying action on adjunvant arthritis in the rat. Int J Immopharmacol 1988; 7: 7-18.
11. Thoenes G, Sitter T, Langer K, Bartlett R, Schleyerbach R. Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in rats. Int J Immopharmacol 1989; 8: 921-9.
12. Ogawa T, Inazu M, Gotoh K, Inoue T, Hayashi S. Therapeutic effects of leflunomide, a new antirheumatic drug, on glomerulonephritis induced by anti-basement membrane antibodyy in rats. Clin Immunol Immunopathol 1991; 6: 103-18.
13. Vidic-Dankovic B, Damjanovic M, Apostolski S, Isakovic K, Bartlett R. Leflunomide prevents the development of experimentally induced myasthenia gravis. Int J Immopharmacology 1995; 14: 273-81.
14. Kremer JM. Methotrexate and leflunomide: biochemical basis for combination therapy inthe treatment of rheumatoid arthritis. Sem Arthritis Rheum 1999; 29: 14-26.
15. Fox RI. Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol 1998; 25 (Supl 53): 20-6.
16. Fox RI, Herrmann ML, Frangou CG, Whal GM, Morris RE, Strand V et al. Mechanism of action of leflunomide in rheumatoid arthritis. Clin Immunol 1999; 93: 198-208.
17. Kraan MC, Reece RJ, Barg EC, Breedveld FC, Emery P, Farnell J et al. Expression of ICAM-1 and MMP-1 in rheumatoid synovialtissue after treatment with leflunomide. Arthritis Rheum 1999; 42 (Supl): 162-548.
18. Kraan MC, Koster BM, Elferink JG, Post WJ, Breedveld FC, Tak PP et al. Leflunomide inhibits neutrophil migration early after initiation of treatment in rheumatoid arthritis patients. Arthritis Rheum 1999; 42 (Supl): 192.
19. Cao W, Kao P, Aoki Y, Xu JC, Shorthouse RA, Morris RE. A novel mechanism of action of the immunomodulatory drug, leflunomide: augmentation of the immunosuppressive cytokine, TGFβ 1, and suppression of the immunostimulatory cytokine, IL-2. Transplant Proc 1996; 28: 3079-80.
20. Benito Guzmán MJ. Efecto de la ciclosporina en la modulación de la inflamación y la fibrogénesis en la artritis experimental [tesis doctoral]. Madrid: UAM. Departamento de Biología Molecular, 2000.
21. Miladenovic V, Domijan Z, Rozman B, Jajic B, Mihailovic J, Dorderic D et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis: results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 1995; 38: 1595-603.
22. Rozman B. Clinical experience with leflunomide in rheumatoid arthritis. J Rheumatol 1998; 25 (supl 53): 27-32.
23. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in blind, randomised, multicentre trial. Lancet 1999; 353: 259-66.
24. Strand V, Tugwell P, Bombardier C, Maetzela A, Crowford B, Dorrier C et al. Function and health-related quality of life. Results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42: 1870-8.
25. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999; 159: 2542-50.
26. Weinblatt ME, Kremer JM, Coblyn JS, Weaver A, Fleischmann R, Cannon G et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42: 1322-8.
27. Miller ML, Morton GL, Anderson LG, Keroack BJ, Portland CD. Early community-based experience with leflunomide in the treatment of rheumatoid arthritis. Artritis Rheum 1999; 42 (Supl): 79.
28. Emery P, Breedveld FC, Jubb RW, Sorensen H, Oed C, Loew-Friedrich J, et al. Efficacy and safety of leflunomide vs methotrexate in rheumatoid arthritis: results of a double-blind randomized, 2 year trial. Artritis Rheum 1999; 42 (supl): 271.
29. Kalden JR, Schattenkirchner M, Smolen J, Scott DJ, Loew-Friedrich I a Oed C et al. Leflunomide vs sulfasalazine in rheumatoid arthritis: 24 month update of a randomized double-blind study. Artritis Rheum 1999; 42 (Supl): 272.
30. Cohen S, Weaver A, Schiff M, Strand V. Two' year treatment of active rheumatoid arthritis with leflunomide compared with placebo or methotrexate. Artritis Rheum 1999; 42 (Supl): 273.